Sanofi‘s and Regeneron Pharmaceuticals‘ alirocumab, an investigational MAb targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), has met its primary efficacy endpoint in a Phase III trial as a monotherapy. The mean low-density lipoprotein-cholesterol (LDL-C) reduction from baseline to week 24 was significantly greater in patients randomized to alirocumab, as compared to patients randomized to Zetia (ezetimibe): 47.2% vs. 15.6%. Most of the companies’ Phase III trial...